drugset / Trial / NCT03127319
A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell lung cancer with bone metastases.
Timeline
- Start
- 2017-07-03
- Primary completion
- 2019-04
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |
| Comparator | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Comparator | Zoledronic acid | Other / unclassified | 4 mg | Intravenous |